• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Two long-lasting human monoclonal antibodies cross-react with monkeypox virus A35 antigen - Nature Correspondence

Mary Wilson

Well-known member
Published 25 May 2023

DOI https://doi.org/10.1038/s41421-023-00556-w

Zhou, B., Wang, H., Cheng, L. et al.

Dear Editor,

Human monkeypox has been a rare zoonotic disease caused by the monkeypox virus (MPXV) infection which is mainly reported in West and Central Africa in the past[SUP]1[/SUP]. However, since the first confirmed case was found in the United Kingdom on May 7, 2022, there were over 87,000 confirmed cases worldwide until April, 2023 (https://worldhealthorg.shinyapps.io/mpx_global/). Human monkeypox seems to have become a multi-country outbreak disease and it was declared a Public Health Emergency of International Concern by the World Health Organization on July 23, 2022.

MPXV belongs to a member of Orthopoxvirus (OPXV) genus and is close to the infamous smallpox virus, yet causing relatively milder illness in humans[SUP]2[/SUP]. MPXV infection causes 3.6% and 10.6% fatality in the West African clade and the Central African clade, respectively[SUP]3,4[/SUP]. MPXV has a broad host range and many mammalian cells are susceptible to its infection[SUP]5[/SUP]. Smallpox vaccines are hopeful to fight against MPXV, which could provide about 85% protection[SUP]6[/SUP], and could induce long-term humoral immunity for up to 75 years[SUP]7,8[/SUP]. In this study, we evaluated the cross-recognization of this preexisting humoral immune response to MPXV including circulating polyclonal antibodies (pAbs) and memory B cells (MBCs), and revealed the key features of two isolated monoclonal antibodies (mAbs).

OPXV contains two kinds of virions, mature virion (MV) and enveloped virion (EV), carrying different surface antigens[SUP]9[/SUP]. Taking vaccinia virus (VACV) as an example, several neutralizing antibody targets have been identified, such as L1, H3, A13, A17, and A27, and etc. on the MV and B5 and A33 on the EV[SUP]3[/SUP]. We selected four representative homologous proteins of MPXV (H3 (equivalent to H3 in VACV) and A29 (A27 in VACV) on the MV; B6 (B5 in VACV) and A35 (A33 in VACV) on the EV)[SUP]10[/SUP], to detect the long-lasting antibody cross-binding to the MPXV in humans. ...

https://www.nature.com/articles/s41421-023-00556-w#citeas
 
Back
Top